Lung and Gut Microbiota As Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2019 Dec 13

PMID 31827379

Citations 25

Authors

Carmine Carbone

Geny Piro

Vincenzo Di Noia

Ettore DArgento

Emanuele Vita

Miriam Grazia Ferrara

Sara Pilotto

Michele Milella

Giovanni Cammarota

Antonio Gasbarrini

Giampaolo Tortora

Emilio Bria

Affiliations

Soon will be listed here.

Abstract

Lung cancer is one of the deadliest and most common malignancies in the world, representing one of the greatest challenges in cancer treatment. Immunotherapy is rapidly changing standard treatment schedule and outcomes for patients with advanced malignancies. However, several ongoing studies are still attempting to elucidate the biomarkers that could predict treatment response as well as the new strategies to improve antitumor immune system response ameliorating immunotherapy efficacy. The complex of bacteria, fungi, and other microorganisms, termed microbiota, that live on the epithelial barriers of the host, are involved in the initiation, progression, and dissemination of cancer. The functional role of microbiota has attracted an accumulating attention recently. Indeed, it has been demonstrated that commensal microorganisms are required for the maturation, education, and function of the immune system regulating the efficacy of immunotherapy in the anticancer response. In this review, we discuss some of the major findings depicting bacteria as crucial gatekeeper for the immune response against tumor and their role as driver of immunotherapy efficacy in lung cancer with a special focus on the distinctive role of gut and lung microbiota in the efficacy of immunotherapy treatment.

Citing Articles

Plant-nanoparticles enhance anti-PD-L1 efficacy by shaping human commensal microbiota metabolites.

Teng Y, Luo C, Qiu X, Mu J, Sriwastva M, Xu Q Nat Commun. 2025; 16(1):1295.

PMID: 39900923 PMC: 11790884. DOI: 10.1038/s41467-025-56498-2.

The Influence of the Gut Microbiota on Host Health: A Focus on the Gut-Lung Axis and Therapeutic Approaches.

Alswat A Life (Basel). 2024; 14(10).

PMID: 39459579 PMC: 11509314. DOI: 10.3390/life14101279.

Microbiome bacterial influencers of host immunity and response to immunotherapy.

Yousefi Y, Baines K, Maleki Vareki S Cell Rep Med. 2024; 5(4):101487.

PMID: 38547865 PMC: 11031383. DOI: 10.1016/j.xcrm.2024.101487.

Lung cancer, comorbidities, and medication: the infernal trio.

Pluchart H, Chanoine S, Moro-Sibilot D, Chouaid C, Frey G, Villa J Front Pharmacol. 2024; 14:1016976.

PMID: 38450055 PMC: 10916800. DOI: 10.3389/fphar.2023.1016976.

Host Transcriptional Regulatory Genes and Microbiome Networks Crosstalk through Immune Receptors Establishing Normal and Tumor Multiomics Metafirm of the Oral-Gut-Lung Axis.

Otalora-Otalora B, Lopez-Rivera J, Aristizabal-Guzman C, Isaza-Ruget M, Alvarez-Moreno C Int J Mol Sci. 2023; 24(23).

PMID: 38068961 PMC: 10706695. DOI: 10.3390/ijms242316638.

References

Rossen N, Fuentes S, van der Spek M, Tijssen J, Hartman J, Duflou A . Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. 2015; 149(1):110-118.e4. DOI: 10.1053/j.gastro.2015.03.045. View

Horn L, Spigel D, Vokes E, Holgado E, Ready N, Steins M . Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017; 35(35):3924-3933. PMC: 6075826. DOI: 10.1200/JCO.2017.74.3062. View

Barfod K, Roggenbuck M, Hansen L, Schjorring S, Larsen S, Sorensen S . The murine lung microbiome in relation to the intestinal and vaginal bacterial communities. BMC Microbiol. 2013; 13:303. PMC: 3878784. DOI: 10.1186/1471-2180-13-303. View

Erb-Downward J, Thompson D, Han M, Freeman C, McCloskey L, Schmidt L . Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One. 2011; 6(2):e16384. PMC: 3043049. DOI: 10.1371/journal.pone.0016384. View

Cerutti A, Rescigno M . The biology of intestinal immunoglobulin A responses. Immunity. 2008; 28(6):740-50. PMC: 3057455. DOI: 10.1016/j.immuni.2008.05.001. View

Miura Y, Sunaga N . Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. Cancers (Basel). 2018; 10(8). PMC: 6115923. DOI: 10.3390/cancers10080245. View

He J, Hu Y, Hu M, Li B . Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep. 2015; 5:13110. PMC: 4538573. DOI: 10.1038/srep13110. View

Li W, Deng Y, Chu Q, Zhang P . Gut microbiome and cancer immunotherapy. Cancer Lett. 2019; 447:41-47. DOI: 10.1016/j.canlet.2019.01.015. View

Oshima Y, Tanimoto T, Yuji K, Tojo A . EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(8):1112-1115. PMC: 5885195. DOI: 10.1001/jamaoncol.2017.4526. View

10.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

11.

Horn L, Reck M, Spigel D . The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. Oncologist. 2016; 21(8):910-21. PMC: 4978554. DOI: 10.1634/theoncologist.2015-0523. View

12.

Samuelson D, Welsh D, Shellito J . Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol. 2015; 6:1085. PMC: 4595839. DOI: 10.3389/fmicb.2015.01085. View

13.

Cianci R, Franza L, Schinzari G, Rossi E, Ianiro G, Tortora G . The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer. Int J Mol Sci. 2019; 20(3). PMC: 6387318. DOI: 10.3390/ijms20030501. View

14.

Liu H, Tao L, Zhang J, Zhu Y, Zheng Y, Liu D . Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. Int J Cancer. 2017; 142(4):769-778. DOI: 10.1002/ijc.31098. View

15.

Gupta V, Paul S, Dutta C . Geography, Ethnicity or Subsistence-Specific Variations in Human Microbiome Composition and Diversity. Front Microbiol. 2017; 8:1162. PMC: 5481955. DOI: 10.3389/fmicb.2017.01162. View

16.

Lee Y, Menezes J, Umesaki Y, Mazmanian S . Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2010; 108 Suppl 1:4615-22. PMC: 3063590. DOI: 10.1073/pnas.1000082107. View

17.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

18.

Gollwitzer E, Saglani S, Trompette A, Yadava K, Sherburn R, McCoy K . Lung microbiota promotes tolerance to allergens in neonates via PD-L1. Nat Med. 2014; 20(6):642-7. DOI: 10.1038/nm.3568. View

19.

Bingula R, Filaire M, Radosevic-Robin N, Bey M, Berthon J, Bernalier-Donadille A . Desired Turbulence? Gut-Lung Axis, Immunity, and Lung Cancer. J Oncol. 2017; 2017:5035371. PMC: 5623803. DOI: 10.1155/2017/5035371. View

20.

Renz H, Brandtzaeg P, Hornef M . The impact of perinatal immune development on mucosal homeostasis and chronic inflammation. Nat Rev Immunol. 2011; 12(1):9-23. DOI: 10.1038/nri3112. View